PLX4032 (Vemurafenib) is an 7-azaindole-based, orally-available, inhibitor of the B-Raf V600E mutation with an IC50 of 30 nM. [1&91; In preclinical tumor models, PLX4032 induces antiproliferative effects in both mealonama and thyroid cell lines, with a simultaneous dose-dependent block of MEK1/2 p..

Price: $79.00

AZ628 is a quinazolinone-based pan-Raf kinase inhibitor with IC50 values of 105, 34, and 29 nM for b-Raf, bRafV600E, and c-Raf-1, respectively. [1&91; It is selective over a wide panel of RTKs, including VEGFR2, DDR2, Lyn, Flt1, and FMS. AZ628 inhibits anchorage-dependent and -independent growth, ..

Price: $159.00

GDC0879 is highly selective, orally-bioavailable, oxime-containing pyrazole type inhibitor of B-Raf (V600E) kinase with a potency of 0.13 nM. [1&91; In a screening of a panel of kinases at 1 uM activity only RAF kinases were shown to have >90% inhibition, with only one additional kinase (casein..

Price: $149.00

LX7101 is a pyrrolopyrimidine-based, topically-delivered inhibitor of LIM domain kinase 2 (LIMK2), a kinase associated with the regulation of intraocular pressure. LX7101 acts by enhancing fluid outflow through the trabecular meshwork of the eye. Preclinical studies indicate that LX7101 signifi..

Price: $159.00

LY-2109761 is an orally-bioavailable pyrrolopyrazole inhibitor of the TGF-b1/2 kinase subtypes in Phase I and II clinical studies for malignant malignancies. With Ki potencies of 38 nM and 300 nM, respectively, LY-2109761 has been studied in metastatic pancreatic cancer cells and completely inh..

Price: $159.00

PLX-4720 is an orally-available, ATP-competitive, highly selective, azaindole-based inhibitor of B-Raf (V600E) with IC50 value of 13 nM. PLX-4720 has additional activity towards mutant forms of c-Raf-1 (Y340D, Y341D) at an IC50 of 6.7 nM, with modest single micromolar activity versus kinases su..

Price: $89.00

Sorafenib (BAY 43-9006) is biarylurea-based inhibitor of Raf1 (IC50, 6 nM) with additional activity against B-Raf, mVEGFR2, mPDGFRb (IC50, 22 nM, 15 nM, and 57 nM respectively), and related kinases. [1&91; In MDA-MB-231 breast cancer cells, sorafenib efficiently blocks activation of the MAPK pathw..

Price: $149.00